Pure Financial Advisors LLC Grows Stock Position in Pfizer Inc. (NYSE:PFE)

Pure Financial Advisors LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 13.4% during the fourth quarter, Holdings Channel.com reports. The fund owned 24,966 shares of the biopharmaceutical company’s stock after acquiring an additional 2,945 shares during the period. Pure Financial Advisors LLC’s holdings in Pfizer were worth $662,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Bonness Enterprises Inc. grew its position in Pfizer by 3.4% during the 4th quarter. Bonness Enterprises Inc. now owns 161,508 shares of the biopharmaceutical company’s stock worth $4,285,000 after purchasing an additional 5,300 shares during the last quarter. Amplius Wealth Advisors LLC grew its holdings in shares of Pfizer by 80.7% during the fourth quarter. Amplius Wealth Advisors LLC now owns 46,823 shares of the biopharmaceutical company’s stock valued at $1,242,000 after buying an additional 20,911 shares during the last quarter. Cove Private Wealth LLC increased its position in shares of Pfizer by 693.5% in the 4th quarter. Cove Private Wealth LLC now owns 92,280 shares of the biopharmaceutical company’s stock valued at $2,448,000 after acquiring an additional 80,650 shares during the period. FLC Capital Advisors raised its stake in Pfizer by 22.8% in the 4th quarter. FLC Capital Advisors now owns 47,611 shares of the biopharmaceutical company’s stock worth $1,263,000 after acquiring an additional 8,839 shares during the last quarter. Finally, SFG Wealth Management LLC. acquired a new stake in Pfizer during the 4th quarter worth about $228,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 1.2 %

Shares of PFE opened at $26.63 on Wednesday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market cap of $150.89 billion, a P/E ratio of 35.98, a PEG ratio of 0.63 and a beta of 0.64. The stock’s 50 day moving average is $26.08 and its two-hundred day moving average is $27.98. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm’s revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.17) EPS. Analysts predict that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.46%. Pfizer’s dividend payout ratio (DPR) is currently 227.03%.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Truist Financial reduced their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Guggenheim dropped their price objective on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Sanford C. Bernstein initiated coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price for the company. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, Wolfe Research began coverage on Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $32.00.

Insiders Place Their Bets

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the stock in a transaction on Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now directly owns 10,000 shares in the company, valued at $282,400. This trade represents a 11.11 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.06% of the stock is owned by company insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.